Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRCA1/2 Mutation”

126 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 126 results

Early research (Phase 1)Study completedNCT02482311
What this trial is testing

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

Who this might be right for
Ovarian Cancer, TNBC, SCLC, Other Solid Tumours
AstraZeneca 92
Not applicableStudy completedNCT07416812
What this trial is testing

Targeted Prostate Cancer Screening in Men With BRCA1/2 Mutations

Who this might be right for
Prostate CancerHereditary Prostate Cancer
Institute of Oncology Ljubljana 25
Not applicableStudy completedNCT04683068
What this trial is testing

Promoting Men's Adherence to BRCA1/2 Germline Genetic Testing

Who this might be right for
BRCA1 MutationBRCA2 MutationPsychosocial Factors
European Institute of Oncology 264
Testing effectiveness (Phase 2)Ended earlyNCT02203513
What this trial is testing

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Ovarian CancerBreast CancerProstate Cancer
National Cancer Institute (NCI) 111
Testing effectiveness (Phase 2)Study completedNCT01009788
What this trial is testing

ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast CancerBRCA1 Gene Mutation+1 more
Steven J Isakoff, MD, PhD 63
Testing effectiveness (Phase 2)Ended earlyNCT04171700
What this trial is testing

Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Who this might be right for
Solid Tumor
pharmaand GmbH 83
Early research (Phase 1)Not Yet RecruitingNCT06614751
What this trial is testing

A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway

Who this might be right for
Solid CancersBRCA MutationHRD Cancer+8 more
Danatlas Pharmaceuticals Co., Ltd 112
Early research (Phase 1)Study completedNCT00892736
What this trial is testing

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Who this might be right for
Basal-Like Breast CarcinomaBRCA1 Mutation CarrierBRCA2 Mutation Carrier+14 more
National Cancer Institute (NCI) 98
Testing effectiveness (Phase 2)Study completedNCT02789332
What this trial is testing

Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency

Who this might be right for
Breast CancerTriple Negative Breast NeoplasmsHRpos Breast Neoplasms+1 more
GBG Forschungs GmbH 107
Not applicableLooking for participantsNCT03396341
What this trial is testing

Responses to Genetic Risk Modifier Testing Among Women With Pathogenic Variants in Breast Cancer Predisposition Genes

Who this might be right for
Genetic TestingBRCA1/2
Memorial Sloan Kettering Cancer Center 806
Not applicableLooking for participantsNCT06817694
What this trial is testing

Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 Gene

Who this might be right for
Breast Cancer Susceptibility Gene (BRCA1) MutationBRCA2 MutationFear of Cancer Recurrence
CHU de Quebec-Universite Laval 250
Not applicableActive Not RecruitingNCT05939128
What this trial is testing

A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiA

Who this might be right for
Breast Cancer
AstraZeneca 625
Early research (Phase 1)Looking for participantsNCT04890613
What this trial is testing

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Who this might be right for
Advanced Solid Tumor
Senhwa Biosciences, Inc. 52
Not applicableUnknownNCT01907438
What this trial is testing

Transformation Potential of E2 Exposed Breast Cancer Susceptibility Gene Mutation Heterozygous Epithelial Breast Cells

Who this might be right for
BRCA1 Gene MutationBRCA2 Gene Mutation
Hadassah Medical Organization 30
Large-scale testing (Phase 3)Looking for participantsNCT06580314
What this trial is testing

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Who this might be right for
Fallopian Tube Endometrioid AdenocarcinomaFallopian Tube High Grade Serous AdenocarcinomaFIGO Stage III Ovarian Cancer 2014+6 more
NRG Oncology 880
Testing effectiveness (Phase 2)Ended earlyNCT03140670
What this trial is testing

Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy

Who this might be right for
Pancreatic Cancer
Abramson Cancer Center at Penn Medicine 46
Large-scale testing (Phase 3)Study completedNCT02282020
What this trial is testing

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

Who this might be right for
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
AstraZeneca 266
Not applicableLooking for participantsNCT07532434
What this trial is testing

A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer

Who this might be right for
Ovarian CancerBreast Cancer
Peking University Third Hospital 480
Early research (Phase 1)Ended earlyNCT02561832
What this trial is testing

A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 15
Testing effectiveness (Phase 2)Study completedNCT02401347
What this trial is testing

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

Who this might be right for
Advanced Breast CancerHER2/Neu NegativeTriple-Negative Breast Cancer
Melinda Telli 21
Load More Results